Welcome to our dedicated page for Organogenesis Holdings news (Ticker: ORGO), a resource for investors and traders seeking the latest updates and insights on Organogenesis Holdings stock.
Organogenesis Holdings Inc. (Nasdaq: ORGO) is a pioneering company in the field of regenerative medicine. Headquartered in Canton, Massachusetts, Organogenesis offers a diverse portfolio of bioactive and acellular biomaterial products, primarily targeting the Advanced Wound Care and Surgical & Sports Medicine markets. The company's innovative solutions cater to a wide range of patients with repair and regenerative needs.
The company's core products include PuraPly Antimicrobial, Affinity, NuShield, Apligraf, and Dermagraft, which are designed to improve patient outcomes while reducing overall healthcare costs. Organogenesis is recognized for its advancements in both orthopedics and spine treatments, reflecting its commitment to addressing unmet medical needs through cutting-edge research and development.
In recent news, Organogenesis has reported significant milestones and achievements. The company announced that its Phase 3 randomized control trial evaluating ReNu, a cryopreserved amniotic suspension allograft for knee osteoarthritis (OA), met its primary endpoint, demonstrating a significant reduction in knee OA pain. This achievement is poised to introduce new non-surgical treatment options for OA patients, potentially opening a significant market opportunity for Organogenesis.
The company has also faced challenges. Its third-quarter revenue was impacted by local coverage determination (LCD) issues, yet it managed to deliver substantial improvements in operating profitability and adjusted EBITDA. Organogenesis continues to build momentum with commercial support programs aimed at enhancing customer relationships and regaining lost accounts.
Financially, the company reported a net revenue of $99.7 million in the fourth quarter of 2023, reflecting a decrease from the previous year. Despite these hurdles, Organogenesis remains financially robust with $104.3 million in cash and equivalents as of December 2023. Its operating expenses have been carefully managed, showcasing a reduction in selling, general, and administrative expenses.
Looking ahead, Organogenesis has set optimistic projections for 2024, with anticipated revenue growth driven by new product launches and the continued demonstration of value to customers. The company is also planning to further engage with regulatory bodies to secure approvals and expand the clinical indications of its products.
Overall, Organogenesis Holdings Inc. stands out for its commitment to innovation, patient care, and financial stability, making it a significant player in the regenerative medicine landscape. For more information, visit their official website.
Organogenesis Holdings Inc. (Nasdaq: ORGO) has announced it will release its fourth quarter and fiscal year 2022 financial results after market close on March 1, 2023. Management will hold a conference call at 5:00 p.m. ET on the same day to discuss the financial results and provide a corporate update, followed by a Q&A session. Investors can access the live webcast through the company’s website or via teleconference links provided in the announcement. Organogenesis specializes in regenerative medicine, particularly for advanced wound care and surgical markets, offering innovative product solutions to meet patient needs.
Organogenesis Holdings Inc. (Nasdaq: ORGO) will participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology, and Medtech Conference on December 8, 2022. Held at The Fontainebleau Miami Beach, the event will feature panel discussions and 1x1 meetings with investors. This conference highlights the company’s focus on regenerative medicine, specifically in advanced wound care and surgical solutions. Organogenesis offers a range of bioactive and acellular biomaterials designed to meet diverse patient needs.
Organogenesis Holdings reported third quarter 2022 results with net revenue of $116.9 million, a 3% increase from $113.8 million in Q3 2021. Advanced Wound Care products generated $109.5 million (+2%), while Surgical & Sports Medicine products rose to $7.3 million (+15%). However, net income dropped to $0.2 million from $12.6 million, a significant decrease of $12.4 million. Adjusted net income also fell sharply to $5.1 million, down 68%. The company revised its full-year revenue guidance, anticipating a challenging Q4 due to competitive pressures and reimbursement uncertainties.
Organogenesis Holdings Inc. (Nasdaq: ORGO) announced that it will report its third quarter fiscal year 2022 financial results on November 9, 2022, after market closure. A conference call will follow at 5:00 p.m. ET on the same day, offering a corporate update and a Q&A session. Interested participants can access the call via a live webcast or teleconference, with an archived version available on the company’s website for one year. Organogenesis focuses on regenerative medicine solutions for advanced wound care and surgical markets.
Organogenesis Holdings Inc. (Nasdaq: ORGO) has announced its participation in the Morgan Stanley 20th Annual Global Healthcare Conference, taking place from September 12-14, 2022, at the Sheraton New York Times Square Hotel. The management will engage in a fireside chat on September 13 at 11:45 a.m. Eastern Time. A live audio webcast of the presentation will be available on the company’s website, with a replay accessible for 30 days post-conference. Organogenesis specializes in regenerative medicine, focusing on advanced wound care and surgical solutions.
Organogenesis Receives FDA Clearance for PuraPly MZ
On August 15, 2022, Organogenesis announced the FDA clearance of PuraPly MZ, an innovative powdered product for complex surgical wounds. This marks a significant milestone as it expands their PuraPly portfolio into the surgical and sports medicine markets. PuraPly MZ utilizes native structured collagen to enhance healing in complex wounds, addressing a pressing need in the medical community, with estimates indicating that 28% of surgical sites in the U.S. require specific attention for effective healing.
Organogenesis Holdings Inc. (Nasdaq: ORGO) reported Q2 2022 net revenue of $121.4 million, down 1% year-over-year, with Advanced Wound Care up 2% to $113.8 million while Surgical & Sports Medicine fell 35% to $7.6 million. Net income decreased significantly by 58% to $8.7 million, or $0.07 per share. Adjusted EBITDA dropped to $18.6 million from $25.1 million a year ago. For FY 2022, the company projects revenue between $465 million and $490 million, reflecting a modest annual decline or growth.
Organogenesis Holdings Inc. (Nasdaq: ORGO) announced its second quarter fiscal year 2022 financial results will be released after market close on August 9, 2022. A conference call will follow at 5:00 p.m. Eastern Time, providing an overview of the results and corporate updates. Interested participants can access the live webcast through the company's investor relations website. The archived version will also be available for roughly one year. Organogenesis specializes in regenerative medicine, focusing on products for Advanced Wound Care and Surgical & Sports Medicine.
Organogenesis Holdings Inc. (Nasdaq: ORGO) reported Q1 2022 financial results with net revenue of $98.1 million, down 4% year-over-year. Revenue from Advanced Wound Care increased by 0.3% to $91.0 million, while Surgical & Sports Medicine revenue fell 39% to $7.2 million. Net income plummeted to $0.1 million from $9.9 million, a decrease of $9.9 million. Adjusted EBITDA also dropped 69% to $5.0 million. The company projects net revenue for 2022 to be between $485 million and $515 million, indicating an anticipated growth of 4% to 10%.
Organogenesis Holdings Inc. (Nasdaq: ORGO) has announced the appointments of Michele Korfin and Gilberto Quintero, Ph.D. to its Board of Directors, effective May 3, 2022. Both directors bring extensive experience from various leadership roles in the healthcare industry. Korfin, with previous roles at Gamida Cell and Kite Pharma, holds an MBA from Harvard and has a strong background in market access and commercialization. Quintero has served as Chief Quality Officer at Kimberly-Clark and holds a Ph.D. in Chemistry. This move enhances the board's independence, with a majority now being independent directors.
FAQ
What is the current stock price of Organogenesis Holdings (ORGO)?
What is the market cap of Organogenesis Holdings (ORGO)?
What is Organogenesis Holdings Inc.?
Where is Organogenesis Holdings Inc. headquartered?
What are some of the core products of Organogenesis?
What recent achievement has Organogenesis announced?
How did Organogenesis perform financially in the fourth quarter of 2023?
What are the future prospects for Organogenesis?
What markets does Organogenesis target?
What is the significance of ReNu in Organogenesis's portfolio?
How does Organogenesis contribute to healthcare cost reduction?
Where can more information about Organogenesis be found?
